Pipeline Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Pharmaceutical TechnologyBiogen plans to pause or terminate investment in most of Apellis' legacy research programmes, while cutting some of its workforce.Immunology & InflammationRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce. Immunology & Inflammation Read full story Post navigation Previous: Viridian wins FDA approval for Lumvoa for thyroid eye diseaseNext: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
